3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
103
Lymphoma
68
Lymphoma, Large B-Cell, Diffuse
49
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Sarcoma
33
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Leukemia
23
Burkitt Lymphoma
22
Neoplasms
19
Lymphoma, Mantle-Cell
18
Triple Negative Breast Neoplasms
15
Multiple Myeloma
15
Lymphoma, Follicular
15
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Anaplastic
12
Carcinoma, Hepatocellular
12
Breast Neoplasms, Male
11
Neuroblastoma
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Inflammatory Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, T-Cell
8
Osteosarcoma
7
Fallopian Tube Neoplasms
7
Urinary Bladder Neoplasms
6
Liposarcoma
6
Interventions
tremelimumab
1
trametinib
1
pazopanib
1
eribulin
1
durvalumab
1
HhAntag691
1
Gemcitabine
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Hemangioendothelioma, Epithelioid
×
Doxorubicin
×
Clear all
No trials found.